Artiva Biotherapeutics (ARTV) Change in Acquisitions & Divestments (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Change in Acquisitions & Divestments for 4 consecutive years, with $22.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 24.14% year-over-year to $22.0 million; the TTM figure through Mar 2026 stood at $103.9 million (up 49.78% YoY), while the FY2025 annual figure was $110.9 million, up 96.76% from the prior year.
• Change in Acquisitions & Divestments slipped to $22.0 million in Q1 2026 per ARTV's latest filing, from $24.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $29.6 million in Q3 2025 and bottomed at $12.0 million in Q3 2023.
• Historically, Change in Acquisitions & Divestments has averaged $19.5 million across 4 years, with a median of $16.0 million in 2024.
• Annual changes were most pronounced in 2025 — Change in Acquisitions & Divestments surged 138.9% — and 2026, when it decreased 24.14%.
• Artiva Biotherapeutics' Change in Acquisitions & Divestments stood at $12.8 million in 2023, then grew by 8.98% to $14.0 million in 2024, then jumped by 72.04% to $24.0 million in 2025, then fell by 8.33% to $22.0 million in 2026.
• Business Quant data shows ARTV's Change in Acquisitions & Divestments at $22.0 million in Q1 2026, $24.0 million in Q4 2025, and $29.6 million in Q3 2025.